Melatonin therapy reduces the risk of osteoporosis and normalizes bone formation in multiple sclerosis
Melatonin therapy reduces the risk of osteoporosis and normalizes bone formation in multiple sclerosis
复制标题
DOI：
10.1111/fcp.12337
复制
发表时间：
2018-04-01
影响因子：
2.9
通讯作者：
Farhadi, Naser
中科院分区：
文献类型：
--
作者：
Ghareghani, Majid;Scavo, Linda;Farhadi, Naser
多发性硬化（MS）是一种常见的中枢神经系统自身免疫性和神经退行性疾病。MS患者的血清褪黑激素水平降低，他们也有骨质疏松症的风险。降钙素原（proCT）已被报道为全身性炎症和自身免疫性疾病的生物标志物;然而，其在MS患者中的变化尚未得到充分研究。本研究使用ELISA调查MS患者中血清褪黑激素与proCT之间的临床相关性。然后，我们评估了褪黑激素（10 mg/kg）治疗对MS实验性自身免疫性脑脊髓炎（EAE）模型和MS患者骨代谢和骨质疏松症的影响。数据显示显著增加（*P
Multiple sclerosis (MS) is a common autoimmune and neurodegenerative disease of the central nervous system. Serum levels of melatonin decrease in MS patients who are also at risk of osteoporosis. Procalcitonin (proCT) has been reported as a biomarker of systemic inflammation and autoimmune disease; however, its changes in MS patients have not been well explored. This study investigated, using ELISA, the clinical correlation between serum melatonin and proCT in MS patients. We then assessed the effect of melatonin (10mg/kg) therapy on bone metabolism and osteoporosis in experimental autoimmune encephalomyelitis (EAE) model of MS and in MS patients. Data showed a significant increase (*P